Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...